Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525298 · ClinicalTrials.gov registry record · Phase 1
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency, sponsored by Eisbach Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT06525298: Recruiting Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency, sponsored by Eisbach Bio.
NCT06525298 is a Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency that is actively recruiting participants, run by Eisbach Bio. The registered enrollment target is 144 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525298, a Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency, is actively recruiting participants, sponsored by Eisbach Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Primary Outcome
Number and percentage of participants with adverse events, serious adverse events, adverse events of special interest including changes in safety lab parameters, physical examinations, vital signs, and electrocardiogram (ECG)
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Trastuzumab deruxtecan
- DRUG EIS-12656
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT06525298 shows while recruiting
NCT06525298 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% lower).
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.
NCT06525298 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06525298 about?
NCT06525298 is a clinical study titled "EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors". This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
What is the current status of trial NCT06525298?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-09-09. Estimated completion is 2027-12.
What conditions does trial NCT06525298 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency.
What interventions are being tested in trial NCT06525298?
The interventions under investigation include: Olaparib (DRUG), Trastuzumab deruxtecan (DRUG), EIS-12656 (DRUG).
Who is sponsoring clinical trial NCT06525298?
This trial is sponsored by Eisbach Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06525298 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06525298's enrollment target sits among peer trials
144 92nd of 189 higher than 97 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI